SG11202006990TA - Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent - Google Patents
Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agentInfo
- Publication number
- SG11202006990TA SG11202006990TA SG11202006990TA SG11202006990TA SG11202006990TA SG 11202006990T A SG11202006990T A SG 11202006990TA SG 11202006990T A SG11202006990T A SG 11202006990TA SG 11202006990T A SG11202006990T A SG 11202006990TA SG 11202006990T A SG11202006990T A SG 11202006990TA
- Authority
- SG
- Singapore
- Prior art keywords
- plinabulin
- administration
- composition
- induced neutropenia
- reducing chemotherapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862625290P | 2018-02-01 | 2018-02-01 | |
| US201862713486P | 2018-08-01 | 2018-08-01 | |
| US201862749060P | 2018-10-22 | 2018-10-22 | |
| US201862757648P | 2018-11-08 | 2018-11-08 | |
| PCT/US2019/015867 WO2019152530A1 (en) | 2018-02-01 | 2019-01-30 | Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006990TA true SG11202006990TA (en) | 2020-08-28 |
Family
ID=67479904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006990TA SG11202006990TA (en) | 2018-02-01 | 2019-01-30 | Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210030843A1 (https=) |
| EP (1) | EP3746076A4 (https=) |
| JP (3) | JP2021512121A (https=) |
| KR (2) | KR20200116477A (https=) |
| CN (1) | CN112105363A (https=) |
| AU (1) | AU2019216305B2 (https=) |
| BR (1) | BR112020015758A2 (https=) |
| CA (1) | CA3089391A1 (https=) |
| IL (1) | IL276197A (https=) |
| SG (1) | SG11202006990TA (https=) |
| WO (1) | WO2019152530A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383691B (es) | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| WO2017139231A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| RU2760348C2 (ru) | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| US11267858B2 (en) | 2019-05-31 | 2022-03-08 | Spectrum Pharmaceuticals, Inc. | Methods of treatment using G-CSF protein complex |
| US11684655B2 (en) | 2019-05-31 | 2023-06-27 | Spectrum Pharmaceuticals, Inc. | Methods of treating neutorpenia using G-CSF protein complex |
| EP4045046A4 (en) * | 2019-10-15 | 2024-01-10 | Beyondspring Pharmaceuticals Inc. | Methods and compositions for treating iron disorders |
| JP2023505506A (ja) * | 2019-12-05 | 2023-02-09 | ハンミ ファーマシューティカルズ カンパニー リミテッド | 化学療法または放射線療法で誘導された好中球減少症を治療する方法 |
| CA3186416A1 (en) * | 2020-07-17 | 2022-01-20 | John A. Barrett | Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complex |
| WO2022133492A1 (en) * | 2020-12-18 | 2022-06-23 | Beyondspring Pharmaceuticals, Inc. | Compositions and methods for generating anti-tumor immune response |
| KR102375269B1 (ko) * | 2021-01-27 | 2022-03-17 | 한미약품 주식회사 | 단백질 액상 제제 및 이의 제조방법 |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| FI131561B1 (en) * | 2023-12-28 | 2025-06-30 | Faron Pharmaceuticals Oy | CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY |
| CN120682197A (zh) * | 2024-03-19 | 2025-09-23 | 大连万春布林医药有限公司 | 普那布林的盐晶型 |
| CN119371407A (zh) * | 2024-06-27 | 2025-01-28 | 青岛海合生物科技有限公司 | 一种具有抗肿瘤功效的2,5-二酮哌嗪类化合物及其在制备治疗和/或预防中性粒细胞减少症的药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110132327A (ko) * | 2009-01-16 | 2011-12-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 재조합 인간 알부민-인간 과립구 콜로니 자극 인자 융합 단백질의 신규 안정한 제형 |
| JP6411523B2 (ja) * | 2013-10-11 | 2018-10-24 | ビヨンドスプリング インコーポレイテッド | プリナブリン及びタキサンの組合せがん治療 |
| RU2760348C2 (ru) * | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| BR112019015974A2 (pt) * | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
-
2019
- 2019-01-30 KR KR1020207024515A patent/KR20200116477A/ko not_active Ceased
- 2019-01-30 CA CA3089391A patent/CA3089391A1/en active Pending
- 2019-01-30 BR BR112020015758-9A patent/BR112020015758A2/pt unknown
- 2019-01-30 US US16/966,156 patent/US20210030843A1/en active Pending
- 2019-01-30 CN CN201980018772.9A patent/CN112105363A/zh active Pending
- 2019-01-30 SG SG11202006990TA patent/SG11202006990TA/en unknown
- 2019-01-30 JP JP2020541924A patent/JP2021512121A/ja active Pending
- 2019-01-30 KR KR1020267003258A patent/KR20260023097A/ko active Pending
- 2019-01-30 AU AU2019216305A patent/AU2019216305B2/en active Active
- 2019-01-30 WO PCT/US2019/015867 patent/WO2019152530A1/en not_active Ceased
- 2019-01-30 EP EP19746727.7A patent/EP3746076A4/en active Pending
-
2020
- 2020-07-21 IL IL276197A patent/IL276197A/en unknown
-
2023
- 2023-11-30 JP JP2023202765A patent/JP2024015120A/ja active Pending
-
2025
- 2025-12-05 JP JP2025234643A patent/JP2026026377A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210030843A1 (en) | 2021-02-04 |
| IL276197A (en) | 2020-09-30 |
| CA3089391A1 (en) | 2019-08-08 |
| KR20260023097A (ko) | 2026-02-20 |
| JP2021512121A (ja) | 2021-05-13 |
| EP3746076A1 (en) | 2020-12-09 |
| WO2019152530A1 (en) | 2019-08-08 |
| JP2026026377A (ja) | 2026-02-16 |
| JP2024015120A (ja) | 2024-02-01 |
| RU2020126600A (ru) | 2022-03-01 |
| KR20200116477A (ko) | 2020-10-12 |
| EP3746076A4 (en) | 2021-12-22 |
| NZ766454A (en) | 2024-02-23 |
| AU2019216305B2 (en) | 2024-11-21 |
| BR112020015758A2 (pt) | 2020-12-08 |
| AU2019216305A1 (en) | 2020-08-27 |
| CN112105363A (zh) | 2020-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276197A (en) | Composition and method for reducing the neutrophil deficiency caused by chemotherapy through the administration of palinabolin and G-CSF factor | |
| IL283177A (en) | Preparations and methods for delivering a specific charge to a cell | |
| SG11202106144VA (en) | Compositions for the delivery of therapeutic agents and methods of use and making thereof | |
| IL276464A (en) | Methods and preparations for administering therapeutic protein | |
| IL276148A (en) | A preparation and method for reducing platelet count through the administration of palinabolin | |
| IL260515B1 (en) | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone | |
| IL270812B1 (en) | Solid preparations for oral administration containing semaglutide and dapagliflozin and their use in medicine | |
| EP3714887A4 (en) | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION AND RELATED PREPARATION PROCESS | |
| IL276244A (en) | A pharmaceutical preparation for the eyes, a method for its preparation and its application | |
| EP3838265A4 (en) | INJECTABLE PHARMACEUTICAL COMPOSITION AND METHOD FOR PREPARATION | |
| IL291601B2 (en) | Neoglycoconjugates as vaccines and therapeutic tools | |
| EP3824888A4 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING FAB I INHIBITORS AND METHOD FOR PREPARING IT | |
| IL287137A (en) | Preparations and methods for administration of healing substances | |
| EP3749370C0 (de) | Pharmazeutische formulierungen, verfahren zum herstellen einer pharmazeutischen formulierung sowie ein arzneimittel umfassend eine solche | |
| ZA202008034B (en) | Ivosidenib forms and pharmaceutical compositions | |
| PL4048230T3 (pl) | Doustne kompozycje gliptiny i sposób ich wytwarzania | |
| TR201722603A2 (tr) | Metformi̇n ve si̇tagli̇pti̇n i̇çeren sicak eri̇tme ekstrüzyonu i̇le gerçekleşti̇ri̇len tablet formülasyonlari | |
| EP3813842A4 (en) | PHARMACEUTICAL COMPOSITION AND MANUFACTURING PROCESS THEREOF | |
| EP3381467A4 (en) | PHARMACEUTICAL VACCINE COMPOSITION FOR ORAL ADMINISTRATION AND METHOD FOR PREPARING A PHARMACEUTICAL VACCINE COMPOSITION FOR ORAL ADMINISTRATION | |
| ZA202104261B (en) | Combination pharmaceutical compositions and methods thereof | |
| EP3781194A4 (en) | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF THERAPEUTIC AND IMAGING AGENTS | |
| SG11202101547WA (en) | Pharmaceutical composition for oral administration | |
| PL3898596T3 (pl) | Związek farmaceutyczny, sposób jego wytwarzania i jego zastosowanie jako środek medyczny | |
| MX2019008847A (es) | Profarmacos de cisteamina. | |
| HK40047072A (en) | Compositions and methods for the selective delivery of therapeutic and imaging agents |